Cargando…
GB-2 inhibits ACE2 and TMPRSS2 expression: In vivo and in vitro studies
After the first case of Coronavirus disease 2019 (COVID-19) was reported in Wuhan, COVID-19 has rapidly spread to almost all parts of world. Angiotensin converting enzyme 2 (ACE2) receptor can bind to spike protein of SARS-CoV-2. Then, the spike protein of SARS-CoV-2 can be cleaved and activated by...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Author(s). Published by Elsevier Masson SAS.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7547400/ https://www.ncbi.nlm.nih.gov/pubmed/33049583 http://dx.doi.org/10.1016/j.biopha.2020.110816 |
_version_ | 1783592413123575808 |
---|---|
author | Wu, Ching-Yuan Lin, Yu-Shih Yang, Yao-Hsu Shu, Li-Hsin Cheng, Yu-Ching Liu, Hung Te |
author_facet | Wu, Ching-Yuan Lin, Yu-Shih Yang, Yao-Hsu Shu, Li-Hsin Cheng, Yu-Ching Liu, Hung Te |
author_sort | Wu, Ching-Yuan |
collection | PubMed |
description | After the first case of Coronavirus disease 2019 (COVID-19) was reported in Wuhan, COVID-19 has rapidly spread to almost all parts of world. Angiotensin converting enzyme 2 (ACE2) receptor can bind to spike protein of SARS-CoV-2. Then, the spike protein of SARS-CoV-2 can be cleaved and activated by transmembrane protease, serine 2 (TMPRSS2) of the host cells for SARS-CoV-2 infection. Therefore, ACE2 and TMPRSS2 are potential antiviral targets for treatment of prevention of SARS-CoV-2 infection. In this study, we discovered that 10−250 μg/mL of GB-2, from Tian Shang Sheng Mu of Chiayi Puzi Peitian Temple, can inhibit ACE2 mRNA expression and ACE2 and TMPRSS2 protein expression in HepG2 and 293 T cells without cytotoxicity. GB-2 treatment could decrease ACE2 and TMPRSS2 expression level of lung tissue and kidney tissue without adverse effects, including nephrotoxicity and hepatotoxicity, in animal model. In the compositions of GB-2, we discovered that 50 μg/mL of theaflavin could inhibit protein expression of ACE2 and TMPRSS2. Theaflavin could inhibit the mRNA expression of ACE2. In conclusion, our results suggest that GB-2 and theaflavin could act as potential compounds for ACE2 and TMPRSS2 inhibitors in the further clinical study. |
format | Online Article Text |
id | pubmed-7547400 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | The Author(s). Published by Elsevier Masson SAS. |
record_format | MEDLINE/PubMed |
spelling | pubmed-75474002020-10-13 GB-2 inhibits ACE2 and TMPRSS2 expression: In vivo and in vitro studies Wu, Ching-Yuan Lin, Yu-Shih Yang, Yao-Hsu Shu, Li-Hsin Cheng, Yu-Ching Liu, Hung Te Biomed Pharmacother Original Article After the first case of Coronavirus disease 2019 (COVID-19) was reported in Wuhan, COVID-19 has rapidly spread to almost all parts of world. Angiotensin converting enzyme 2 (ACE2) receptor can bind to spike protein of SARS-CoV-2. Then, the spike protein of SARS-CoV-2 can be cleaved and activated by transmembrane protease, serine 2 (TMPRSS2) of the host cells for SARS-CoV-2 infection. Therefore, ACE2 and TMPRSS2 are potential antiviral targets for treatment of prevention of SARS-CoV-2 infection. In this study, we discovered that 10−250 μg/mL of GB-2, from Tian Shang Sheng Mu of Chiayi Puzi Peitian Temple, can inhibit ACE2 mRNA expression and ACE2 and TMPRSS2 protein expression in HepG2 and 293 T cells without cytotoxicity. GB-2 treatment could decrease ACE2 and TMPRSS2 expression level of lung tissue and kidney tissue without adverse effects, including nephrotoxicity and hepatotoxicity, in animal model. In the compositions of GB-2, we discovered that 50 μg/mL of theaflavin could inhibit protein expression of ACE2 and TMPRSS2. Theaflavin could inhibit the mRNA expression of ACE2. In conclusion, our results suggest that GB-2 and theaflavin could act as potential compounds for ACE2 and TMPRSS2 inhibitors in the further clinical study. The Author(s). Published by Elsevier Masson SAS. 2020-12 2020-10-10 /pmc/articles/PMC7547400/ /pubmed/33049583 http://dx.doi.org/10.1016/j.biopha.2020.110816 Text en © 2020 The Author(s) Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Original Article Wu, Ching-Yuan Lin, Yu-Shih Yang, Yao-Hsu Shu, Li-Hsin Cheng, Yu-Ching Liu, Hung Te GB-2 inhibits ACE2 and TMPRSS2 expression: In vivo and in vitro studies |
title | GB-2 inhibits ACE2 and TMPRSS2 expression: In vivo and in vitro studies |
title_full | GB-2 inhibits ACE2 and TMPRSS2 expression: In vivo and in vitro studies |
title_fullStr | GB-2 inhibits ACE2 and TMPRSS2 expression: In vivo and in vitro studies |
title_full_unstemmed | GB-2 inhibits ACE2 and TMPRSS2 expression: In vivo and in vitro studies |
title_short | GB-2 inhibits ACE2 and TMPRSS2 expression: In vivo and in vitro studies |
title_sort | gb-2 inhibits ace2 and tmprss2 expression: in vivo and in vitro studies |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7547400/ https://www.ncbi.nlm.nih.gov/pubmed/33049583 http://dx.doi.org/10.1016/j.biopha.2020.110816 |
work_keys_str_mv | AT wuchingyuan gb2inhibitsace2andtmprss2expressioninvivoandinvitrostudies AT linyushih gb2inhibitsace2andtmprss2expressioninvivoandinvitrostudies AT yangyaohsu gb2inhibitsace2andtmprss2expressioninvivoandinvitrostudies AT shulihsin gb2inhibitsace2andtmprss2expressioninvivoandinvitrostudies AT chengyuching gb2inhibitsace2andtmprss2expressioninvivoandinvitrostudies AT liuhungte gb2inhibitsace2andtmprss2expressioninvivoandinvitrostudies |